Consolidated Statement Of Profit Or Loss

Astellas Pharma Inc. - Filing #7332273

Concept 2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
Consolidated statement of profit or loss
Statement of profit or loss
Revenue
1,603,672,000,000 JPY
1,518,619,000,000 JPY
Cost of sales
292,485,000,000 JPY
288,353,000,000 JPY
Gross profit
1,311,187,000,000 JPY
1,230,266,000,000 JPY
Selling, general and administrative expenses
740,110,000,000 JPY
630,272,000,000 JPY
Other income
8,691,000,000 JPY
3,642,000,000 JPY
Other expenses
167,814,000,000 JPY
157,515,000,000 JPY
Operating profit (loss)
25,518,000,000 JPY
133,029,000,000 JPY
Finance income
11,455,000,000 JPY
8,110,000,000 JPY
Finance costs
12,005,000,000 JPY
8,779,000,000 JPY
Share of profit (loss) of investments accounted for using equity method
-3,165,000,000 JPY
1,260,000,000 JPY
Profit (loss) before tax
24,969,000,000 JPY
132,361,000,000 JPY
Income tax expense
7,924,000,000 JPY
33,647,000,000 JPY
Profit (loss)
JPY
17,045,000,000 JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
17,045,000,000 JPY
17,045,000,000 JPY
JPY
JPY
JPY
JPY
98,714,000,000 JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
98,714,000,000 JPY
98,714,000,000 JPY
JPY
Profit (loss) attributable to
Owners of parent
17,045,000,000 JPY
98,714,000,000 JPY
Earnings (loss) per share
Basic earnings (loss) per share
9.51
54.24
Diluted earnings (loss) per share
9.47
54.09

Talk to a Data Expert

Have a question? We'll get back to you promptly.